# Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial

> **NCT05372718** · PHASE3 · RECRUITING · sponsor: **Supergene, LLC** · enrollment: 170 (estimated)

## Conditions studied

- Acute Limb Ischemia

## Interventions

- **DRUG:** Recombinant non-immunogenic staphylokinase (Fortelyzin®)
- **PROCEDURE:** surgical methods of treatment

## Key facts

- **NCT ID:** NCT05372718
- **Lead sponsor:** Supergene, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-26
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05372718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05372718, "Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05372718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*